Abrégé

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

Classes IPC  ?

• A61K 39/35 - Allergènes
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to the field of allergens and more specifically to novel allergen isoform variants of Cup s 7 and related allergens containing an isoleucine in position 23. The novel allergen isoform variants find use in the in vitro diagnosis of, treatment and/or prevention of Type I Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

Classes IPC  ?

• A61K 39/36 - Allergènes de pollen
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a dispenser system (200) and a dispenser device (100) for dispensing a vessel (110) from a nested stack of vessels (110) in a hollow carrier (120) The invention also relates to the use of such a dispenser system (200) or dispenser device (100) for dispensing a vessel (110). The invention further relates to a method for manufacturing such a dispenser system (200).

Classes IPC  ?

• A47F 1/08 - Récipients avec dispositifs pour la distribution d'articles la distribution se faisant par le bas
• A47F 1/10 - Récipients avec dispositifs pour la distribution d'articles la distribution se faisant par le bas avec des moyens de distribution mécaniques
• B65G 59/06 - Désempilage par le bas de la pile
• B65G 59/10 - Désempilage d'objets emboîtés

Abrégé

The present invention relates to a method for indicating the presence or absence of Chronic Airflow Limitation (CAL) and/or for determining a predisposition to develop CORD, by determining the concentration of the biomarkers Alpha-1-acid glycoprotein 1 (AGP1) and Histidine-Rich Glycoprotein (HRG), optionally in combination with the biomarker Alpha-1-antitrypsin (a1AT) in said individuals. The present invention is also directed to a method for indicating the presence or absence of Chronic Obstructive Pulmonary Disease (COPD). These findings make it possible to identify individuals and attend to preventive measures before the progress of severe COPD disease in said individuals, but also at a more progressed state of COPD disease.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Awards program for researchers in the field of allergy diagnostics.

Abrégé

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

Classes IPC  ?

• A61K 39/35 - Allergènes
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

in vitroCupressaceaceCupressaceaceCupressaceace pollen-associated food allergies.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 39/35 - Allergènes
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux

Produits et services

Providing reference materials, namely, providing online electronic publications, not downloadable, in the fields of allergies and autoimmune diseases to clinical laboratories. Analytical services, namely, quality evaluation and assessment of clinical test performance and maintenance of good laboratory practices.

Produits et services

Kits containing samples comprising components of human sera, including immunoglobulins, for specific detection of allergens and/or protein markers related to autoimmune disorders for analytical, research and scientific use.

Produits et services

Providing educational information relating to children's allergies via a website.

Abrégé

Methods for harmonization of test results from a biological sample in a multiplexed biochemical assay, wherein presence and/or concentration of multiple biomarkers are determined at the same time in the same sample, making test results obtained in different laboratories comparable comprise: quantifying a presence or concentration of at least two different biomarkers in a biological sample and in a harmonization standard sample, independently in each sample, by means of a defined multiplexed biochemical assay implemented in a defined type of analytical instrument; receiving the test results from the samples into a computer-based decision engine for harmonization of test results from biological samples; and transforming the test results received from the biological sample, which includes transforming the test results from the harmonization standard sample into generalized units and adjusting the test results of the biological sample into the generalized units, GE.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

Abrégé

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen- associated food allergies.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• A61K 39/35 - Allergènes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Providing a website with educational information relating to children's allergies

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer or aggressive prostate cancer. The method is improved by distinguishing between genetic subpopulations with a particularly high risk for prostate cancer or aggressive prostate cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Methods for harmonization of test results from a biological sample in a multiplexed biochemical assay, wherein presence and/or concentration of multiple biomarkers are determined at the same time in the same sample, making test results obtained in different laboratories comparable comprise: quantifying a presence or concentration of at least two different biomarkers in a biological sample and in a harmonization standard sample, independently in each sample, by means of a defined multiplexed biochemical assay implemented in a defined type of analytical instrument; receiving the test results from the samples into a computer-based decision engine for harmonization of test results from biological samples; and transforming the test results received from the biological sample, which includes transforming the test results from the harmonization standard sample into generalized units and adjusting the test results of the biological sample into the generalized units, GE.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• G06F 5/01 - Procédés ou dispositions pour la conversion de données, sans modification de l'ordre ou du contenu des données maniées pour le décalage, p. ex. la justification, le changement d'échelle, la normalisation

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer or aggressive prostate cancer. The method is improved by distinguishing between genetic subpopulations with a particularly high risk for prostate cancer or aggressive prostate cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 39/35 - Allergènes
• A61P 37/08 - Agents antiallergiques

Abrégé

A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%, of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.

Classes IPC  ?

• A61K 39/35 - Allergènes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/35 - Allergènes
• A61K 39/36 - Allergènes de pollen
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 2/00 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• C07K 4/00 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
• C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• A61K 39/35 - Allergènes
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70 % with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/35 - Allergènes
• A61P 37/08 - Agents antiallergiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/12 - Gènes codant pour des protéines animales
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70 % with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4.The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.

Classes IPC  ?

• A61K 39/35 - Allergènes

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs

Abrégé

A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%,of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Produits et services

(1) Chemical products for diagnostic use namely chemical buffer solutions for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic preparations for scientific research purposes for the detection of cancer; diagnostic preparations namely diagnostic preparations for clinical laboratory use (2) Chemical products for diagnostic use namely chemical buffer solutions for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic preparations for scientific research purposes for the detection of cancer; diagnostic preparations namely diagnostic preparations for clinical laboratory use (3) Diagnostic preparations for medical research use; reagents for use in diagnostic tests for medical purposes namely diagnostic reagents for medical laboratory use; chemical test reagents for medical purposes namely reagents for the detection of cancer; diagnostic reagents for scientific research use for the detection of cancer (4) Diagnostic preparations for medical research use; reagents for use in diagnostic tests for medical purposes namely diagnostic reagents for medical laboratory use; chemical test reagents for medical purposes namely reagents for the detection of cancer; diagnostic reagents for scientific research use for the detection of cancer (5) Diagnostic measuring apparatus using using immunoassay and nucleic acid detection technology together with mathematical algorithms to measure cancer associated risks namely medical devices for the qualitative detection of antibodies in human specimens collected as plasma or dried blood spots, mass spectrometers, used for the detection of cancer (6) Diagnostic measuring apparatus using using immunoassay and nucleic acid detection technology together with mathematical algorithms to measure cancer associated risks namely medical devices for the qualitative detection of antibodies in human specimens collected as plasma or dried blood spots, mass spectrometers, used for the detection of cancer (1) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical trials for others; testing of pharmaceuticals (2) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical trials for others; testing of pharmaceuticals (3) Medical services for testing of blood (4) Medical services for testing of blood

Abrégé

The present invention relates to a method which may be used for the analysis of endogenously formed antibodies such as anti-drug antibodies (ADAs) or rheumatoid factor (RF) in a solution, which method comprises (a) contacting the solution with a solid phase to which e.g. IgG molecule(s) have been attached; (b) allowing the ADAs or RF to bind specifically to the attached molecule(s); (c) adding a labeled isotype- specific reagent capable of binding ADAs or RF; (d) removing any excess of reagent; and (f) detecting the label bound or unbound to determine directly or indirectly the presence or concentration of ADAs in the solution. The molecule(s) have been attached to the solid phase via a linker, which may be an organic molecule, an amino acid, a peptide, a protein a molecule of protein origin, a monosaccharide, an oligosaccharide or a polysaccharide. The method according to the invention may be used e.g. as an immunoassay for making clinical decisions in patient care, as well as in the development of new drugs.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 2/00 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• C07K 4/00 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• A61K 39/35 - Allergènes
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for calibrating a multiplex assay, comprising: adding a calibration reagent to a solid phase on which a plurality of capturing agents are immobilized, adding a detection molecule which has a capacity to bind to the calibration reagent, detecting bound detection molecule, thereby creating a calibration curve, wherein the calibration reagent comprises at least two different binding molecules, wherein each binding molecule has a capacity to bind specifically to a capturing agent immobilized on the solid phase and a capacity to bind to a detection molecule. Further provided is a multiplex assay system comprising such a calibration reagent.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Produits et services

Chemicals used in industry and science, including chemical reagents and diagnostic preparations for in vitro use in laboratories and industry. Chemical reagents and diagnostic preparations for medical purposes; chemical reagents and diagnostic preparations for in vitro and in vivo use for medical purposes; in vitro diagnostic tests for medical use. Computer software and analytical instruments for laboratory use. Scientific and technological services and research and design relating thereto. Medical services.

Abrégé

The present invention relates to a method for calibrating a multiplex assay, comprising: adding a calibration reagent to a solid phase on which a plurality of capturing agents are immobilised, adding a detection molecule which has a capacity to bind to the calibration reagent, detecting bound detection molecule, thereby creating a calibration curve, wherein the calibration reagent comprises at least two different binding molecules, wherein each binding molecule has a capacity to bind specifically to a capturing agent immobilised on the solid phase and a capacity to bind to a detection molecule. Further provided is a multiplex assay system comprising such a calibration reagent.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Produits et services

(1) Chemicals used in industry and science, namely chemical reagents and diagnostic preparations for in vitro use in laboratories and industry namely chemicals for use in the pharmaceutical industry, diagnostic reagents for medical laboratory use; chemical reagents and diagnostic preparations for medical purposes namely diagnostic reagents for medical diagnostic and medical research use; chemical reagents and diagnostic preparations for in vitro and in vivo use for medical purposes namely reagents in liquid form for the diagnostic of allergies, asthma, autoimmune diseases; in vitro diagnostic tests for medical use namely test strips for the determination of chemical, biochemical and immunological substances in body fluids, namely blood and urine, cuvettes, cartridges for chemical and immunochemical reagents for in vitro diagnostic testing, test strips for use in in vitro diagnostic examinations; computer software and analytical instruments for laboratory use namely software used to detect and diagnose allergies, asthma and autoimmune diseases and to interpret information pertaining to allergies, asthma and autoimmune diseases. (1) Scientific and technological services and research and design relating thereto in the field of in vitro and in vivo diagnostic of allergies, asthma and autoimmune diseases; medical services namely medical counselling, medical diagnostic services, medical laboratory, medical research and testing services.

Abrégé

An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/35 - Allergènes
• A61K 39/36 - Allergènes de pollen
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Produits et services

Chemicals used in industry and science, including chemical reagents and diagnostic preparations for in vitro use in laboratories and industry. Chemical reagents and diagnostic preparations for medical purposes; chemical reagents and diagnostic preparations for in vitro and in vivo use for medical purposes; in vitro diagnostic tests for medical use. Computer software and analytical instruments for laboratory use. Scientific and technological services and research and design relating thereto. Medical services.

Abrégé

The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis,and IgE-mediated allergy.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for estimation of kinetic characteristics for the formation and dissociation of a complex using lateral flow. The present invention facilitates an easy to use method with high accuracy.

Classes IPC  ?

• G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
• G01N 33/557 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant des mesures cinétiques, c.-à-d. mesure de l'évolution en fonction du temps de l'interaction antigène-anticorps

Abrégé

The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 15/09 - Technologie d'ADN recombinant
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Diagnostic reagents to aid in the medical diagnosis of allergic conditions. Computer software and databases. Processing, storing, controlling and managing of information in databases. Providing access to databases.

Abrégé

A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting (1 10) a plurality of allergens to be tested for in the sample, c) determining (120) for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming (130) each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting (140) determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.

Classes IPC  ?

• A61K 39/35 - Allergènes
• A61P 37/08 - Agents antiallergiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 39/35 - Allergènes
• A61P 37/08 - Agents antiallergiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Produits et services

Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Produits et services

Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Produits et services

Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories. Diagnostic preparations for medical purposes. Diagnostic instruments and apparatus for medical and veterinary purposes.

Produits et services

Diagnostic reagents to aid in the medical diagnosis of allergic conditions. Computer software and databases. Processing, storing, controlling and managing of information in databases. Providing access to databases.

Abrégé

A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, and to travel to a second location downstream of the first location where the mobilized labeled reagent causes a visible change to occur at the second location.

Classes IPC  ?

• G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method enables clinical decision support based on test results for a plurality of tested biomarkers. The method is executed by a data reduction module (15) and comprises the steps of receiving the test results from a testing facility (11); accessing a predefined structure in which available biomarkers are associated with hosts, at least one host being associated with a plurality of biomarkers; identifying a set of hosts by mapping the tested biomarkers to the structure; assigning a host value to each host in said set of hosts based on the test results of the tested biomarker(s) mapped to the host; and providing input data indicative of the set of hosts and the assigned host values for input to a computer-based decision engine (13) for generating the clinical decision support (12). The data reduction module (15) may be included in a system and implemented by computer-executable instructions running on a data processing device, such as a PC or a web server.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Produits et services

Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Produits et services

Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Produits et services

Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.

Abrégé

The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.

Classes IPC  ?

• A61K 39/35 - Allergènes
• A61P 11/06 - Antiasthmatiques
• A61P 37/08 - Agents antiallergiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/86 - Vecteurs viraux
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 39/35 - Allergènes
• A61P 11/06 - Antiasthmatiques
• A61P 37/08 - Agents antiallergiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/35 - Allergènes
• A61K 39/38 - Antigènes de serpents
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• A61K 39/36 - Allergènes de pollen
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A read-out method for a diagnostic point-of-care assay device, the device including a read-out substrate having at least one response area capable of producing a colored indication of a response, the response area including a marker at least one marker whose color changes in response to binding of an analyte thereto and which is used for indication of response. The method includes registering an image of the response area; calculating a color saturation value S for the image using at least two distinct wavelengths; using the S-value for determining a result of the assay. A read-out system (10) for an allergy point-of-care assay device is described. The system includes an illumination device (12; 21, 22) capable of delivering at least two different wavelengths of light; a color image capturing device (14); a control unit (19) for calculating a color saturation value on images recorded by the color image capturing device.

Classes IPC  ?

• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales

Produits et services

Diagnostic preparations for medical purposes.

Abrégé

Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• A61K 39/35 - Allergènes
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Produits et services

(1) Diagnostic preparations for medical purposes namely for diagnosis and monitoring of allergies and asthma

Abrégé

A method enables clinical decision support based on test results for a plurality of tested biomarkers. The method is executed by a data reduction module (15) and comprises the steps of receiving the test results from a testing facility (11); accessing a predefined structure in which available biomarkers are associated with hosts, at least one host being associated with a plurality of biomarkers; identifying a set of hosts by mapping the tested biomarkers to the structure; assigning a host value to each host in said set of hosts based on the test results of the tested biomarker(s) mapped to the host; and providing input data indicative of the set of hosts and the assigned host values for input to a computer-based decision engine (13) for generating the clinical decision support (12). The data reduction module (15) may be included in a system and implemented by computer-executable instructions running on a data processing device, such as a PC or a web server.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)

Abrégé

The invention relates to the design of encoded microparticles. Specifically, certain novel design features which optimise the shape encoding of microparticles with a feature size accessible to low cost optical readers, and with approximately constant surface area, are provided and claimed.

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• G06K 19/06 - Supports d'enregistrement pour utilisation avec des machines et avec au moins une partie prévue pour supporter des marques numériques caractérisés par le genre de marque numérique, p. ex. forme, nature, code

Abrégé

The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as baker s asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• A61K 39/35 - Allergènes
• A61P 11/06 - Antiasthmatiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61P 37/08 - Agents antiallergiques

Abrégé

The present invention relates to the field of allergic diseases, and especially to methods for assessing if symptoms in a patient are related to a hypersensitivity to a specific allergen. Furthermore the invention relates to a computer program product comprising means for controlling the steps of said methods for use with an apparatus for analysis of binding assays. The invention also relates to such an apparatus.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Produits et services

(1) Chemical reagents and diagnostic preparations for medical use in the diagnosis and monitoring of allergies; diagnostic instruments and apparatus for diagnosis and monitoring of allergies

Abrégé

The invention relates to a read-out method for a diagnostic point-of-care assay device, the device comprising a read-out substrate having at least one response area capable of producing a coloured indication of a response, the response area comprising a marker at least one marker the colour of which changes in response to binding of an analyte thereto and which is used for indication of response. The method comprises registering an image of said response area; calculating a colour saturation value S for said image using at least twodistinct wavelengths; using the S-value for determining a result of the assay. Also, the invention relates to a read-out system (10) for an allergy point-of-care assay device (17, 18). The system comprises an illumination device (12; 21, 22) capable of delivering at least two different wavelengths of light; a colour image capturing device (14); a control unit (19) for calculating a colour saturation value (S) on images recorded by the colour image capturing device.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01J 3/50 - Mesure de couleurDispositifs de mesure de couleur, p. ex. colorimètres en utilisant des détecteurs électriques de radiations
• G06T 1/00 - Traitement de données d'image, d'application générale

Abrégé

Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.

Classes IPC  ?

• A61K 39/35 - Allergènes
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• G01N 33/531 - Production de matériaux de tests immunochimiques

Abrégé

Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.

Classes IPC  ?

• A61K 39/35 - Allergènes
• G01N 33/531 - Production de matériaux de tests immunochimiques
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Produits et services

(1) Diagnostic preparations NAMELY for medical DIAGNOSTIC USE, FOR MEDICAL LABORATORY USE, FOR MEDICAL RESEARCH USE; Medical and diagnostic apparatuses and instruments NAMELY IN VITRO TEST SYSTEMS FOR MEDICAL AND VETERINARY USE NAMELY SAMPLE DILUENTS. (2) SOFTWARE USED TO DETECT DISEASES AND INTERPRET INFORMATION. (3) Medical and diagnostic apparatuses and instruments NAMELY IN VITRO TEST SYSTEMS FOR MEDICAL AND VETERINARY USE NAMELY CALIBRATORS, DISPENSERS, PIPES, CARRIER RACKS, TRAYS, MICRO-PLATES, LABEL FOR SAMPLES, MICRO-PLATE COVERS, SAMPLE RACKS.

Abrégé

Lateral flow assay devices and methods for detecting an analyte in a sample which comprises a plurality of nonspecific binding pair members are adapted for two step determinations. In one embodiment, a method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location, allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location and allowing sample to dissolve a water-soluble mark, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample delivery location, and allowing labeled reagent to bind any IgE antibody bound to the immobilized IgE antigen species therein.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Produits et services

Chemical reagents (other than for medical or veterinary purposes); diagnostic preparations, other than for medical or veterinary purposes; diagnostic test kits, not for medical or veterinary use. Pharmaceutical and veterinary preparations; sanitary preparations for medical use; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; chemical reagents for medical or veterinary use; diagnostic preparations for medical use; diagnostic tests for medical or veterinary use. Testing apparatus not for medical purposes; diagnostic apparatus, not for medical purposes. Testing apparatus for medical purposes; diagnostic apparatus for medical purposes; surgical, medical, dental and veterinary apparatus and instruments.

Produits et services

[ Chemical reagents other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; diagnostic test kits consisting of chemical reagents not for medical or veterinary use ] [ Diagnostic preparations for medical use; diagnostic tests consisting of test strips and washing solutions for medical or veterinary use to detect and measure allergy, asthma and autoimmune diseases ] Diagnostic laboratory apparatus, namely, storage trays, storage inserts, namely inserts for storing diluents and strips, loading trays, laboratory bottles; database management software for laboratory testing analysis Blood testing apparatus for medical purposes

Produits et services

Chemical reagents and diagnostic preparations; chemical reagents and diagnostic preparations for in vitro and in vivo use; all the above mentioned goods for medical or veterinary purposes. Diagnostic test apparatus for medical and veterinary use.

Produits et services

In vitro diagnostic tests to be used as an aid in the diagnosis of celiac disease.

Produits et services

Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plaster, material for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.

Produits et services

(1) Chemical reagents (other than for medical or veterinary purposes); diagnostic preparations, other than for medical or veterinary purposes namely kits consisting of reagents (2) Diagnostic preparations for medical purposes namely for use in testing, measuring, monitoring allergies, asthma and autoimmune diseases; diagnostic test kits, for medical or veterinary purposes namely for diagnosing allergies, asthma and autoimmune diseases; chemical reagents for medical or veterinary purposes (3) Diagnostic apparatus for medical purposes namely washers (4) Diagnostic apparatus for medical purposes namely calibrators, carrier storage trays, storage inserts, dispensers, information management software namely for the management of results of blood sample tests in the field of allergy, asthma and autoimmune diseases testing (5) Blood test apparatus and instruments for testing, measuring, monitoring and diagnosis of allergies, asthma and autoimmuned diseases for scientific purposes; diagnostic blood test apparatus and instruments for testing, measuring, monitoring and diagnosis of allergies, asthma and autoimmune diseases; testing apparatus for medical purposes namely automated in vitro test system incorporating sample and reagent handling, washing, reading, calculation, integrated processing and printing, storage of calibration curves

Produits et services

Diagnostic preparations for medical purposes. Medical and diagnostic apparatuses and instruments.

Produits et services

Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry including chemical reagents and diagnostic preparations for in vitro use in laboratories and industry; chemical substances for preserving foodstuffs. Chemical reagents and diagnostic preparations; chemical reagents and diagnostic preparations for in vitro and in vivo use . Diagnotisc test apparatus for medical and veterinary use.

Produits et services

Scientific and technological services and research services, and design services relating thereto; industrial analysis and research services.

Produits et services

(1) Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary purposes and diagnostic preparations for medical and veterinary purposes namely reagents in liquid form for the diagnostic of allergies, asthma, autoimmune diseases; chemical reagents for medical and veterinary purposes; chemical reagents for in vitro use. (2) Diagnostic tests and diagnostic reagents. (3) Software used to detect diseases and interpret information. (4) Diagnostic instruments and apparations namely in vitro test system for medical and veterinary use namely calibrators, dispensers, pipes, carrier racks, trays, microplates, label for samples, sample diluents, microplate covers, sample racks.

Produits et services

Chemicals used in industry and science. Diagnostic preparations for medical purposes. Medical and diagnostic apparatuses and instruments.

Produits et services

Chemical reagents and diagnostic preparations for in vitro use as an aid in clinical diagnosis in scientific laboratories, in the medical and diagnostic industry Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes, diagnostic preparations for medical purposes

Produits et services

In vitro diagnostic tests to be used as an aid in the diagnosis of celiac disease.

Produits et services

(1) Laboratory test to confirm or exclude allergy.